<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091676</url>
  </required_header>
  <id_info>
    <org_study_id>BV 301</org_study_id>
    <nct_id>NCT00091676</nct_id>
    <nct_alias>NCT00001945</nct_alias>
    <nct_alias>NCT00019981</nct_alias>
    <nct_alias>NCT00096577</nct_alias>
  </id_info>
  <brief_title>Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma</brief_title>
  <acronym>BiovaxID</acronym>
  <official_title>Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biovest International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biovest International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase 3 study is to definitively confirm the safety and
      efficacy of BiovaxId, an autologous tumor derived immunoglobulin idiotype vaccine, as
      measured by a significant prolongation of the period of disease free survival when
      administered to patients with indolent follicular Non-Hodgkin's Lymphoma (NHL) during their
      first complete remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Stage III-IV follicular lymphoma and tumor &gt; 2cm (Stage II allowed if tumor &gt;
      5cm), previously untreated by other than local radiation, provide tumor material by tissue
      biopsy for production of a patient-specific Ig idiotype vaccine conjugated to the immunogenic
      protein KLH. After completing PACE or CHOP-R chemotherapy and achieving a complete remission,
      followed by a waiting period to reconstitute the immune system, patients who remain in
      remission randomized to the active treatment arm receive a series of 5 idiotype vaccinations
      accompanied by the immune stimulant GM-CSF. Patients randomized to the control arm receive a
      time-matched series of KLH injections also accompanied by GM-CSF. Patients are subsequently
      studied to observe their immune responses both to the non-specific immune stimulating agents
      and for the specific immune response to the vaccine. Patients are followed for a minimum of 4
      years post-randomization or until relapse.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2000</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate prolongation of the period of Disease Free Survival (significant prolongation of the period of complete remission) in idiotype vaccine treated patients</measure>
    <time_frame>until date of relapse</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the ability of the idiotype vaccine to produce a molecular complete remission</measure>
    <time_frame>once subject achieves molecular CR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the impact of molecular disease free survival</measure>
    <time_frame>until relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the ability of the idiotype vaccine to generate an immunologic response against the NHL tumor</measure>
    <time_frame>varies</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the overall survival of subjects randomized to receive either treatment</measure>
    <time_frame>minimum 5 years from last subject randomized</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To confirm the safety of 5 monthly injections of the vaccine with GM-CSF</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">629</enrollment>
  <condition>Non-Hodgkins Lymphoma</condition>
  <arm_group>
    <arm_group_label>ID-KLH + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH + GM-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FNHLId1</intervention_name>
    <description>5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4</description>
    <arm_group_label>ID-KLH + GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH + GM-CSF</intervention_name>
    <description>5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4</description>
    <arm_group_label>KLH + GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:

          -  Diagnosis of indolent follicular lymphoma(follicular small-cleaved cell, follicular
             mixed or follicular large cell with centrocytes) with surface IgM or IgG phenotype.

          -  Stage III-IV with lymph node &gt; 2cm or Stage II with lymph node &gt; 5 cm

          -  No prior chemotherapy other than local radiation (not greater than 2 sites)

          -  ECOG &lt; 2

          -  Survival &gt; 1 yr

          -  Serum creatinine &lt; 1.5 mg/dl

          -  Bilirubin &lt;1.5 mg/dl

          -  SGOT/SGPT &lt; 3.5 ULN

          -  No HIV antibodies or HBV antigen

          -  Negative pregnancy screen (females)

          -  No unrelated neoplasm in the previous 10 years

          -  No evidence of primary or secondary CNS lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos F Santos, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biovest International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen J Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.biovest.com/</url>
  </link>
  <reference>
    <citation>Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood. 1997 May 1;89(9):3129-35.</citation>
    <PMID>9129015</PMID>
  </reference>
  <reference>
    <citation>Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999 Oct;5(10):1171-7.</citation>
    <PMID>10502821</PMID>
  </reference>
  <reference>
    <citation>Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992 Oct 22;327(17):1209-15.</citation>
    <PMID>1406793</PMID>
  </reference>
  <reference>
    <citation>Dar MM, Kwak LW. Vaccination strategies for lymphomas. Curr Oncol Rep. 2003 Sep;5(5):380-6. Review.</citation>
    <PMID>12895388</PMID>
  </reference>
  <results_reference>
    <citation>Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011 Jul 10;29(20):2787-94. doi: 10.1200/JCO.2010.33.3005. Epub 2011 May 31.</citation>
    <PMID>21632504</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2004</study_first_submitted>
  <study_first_submitted_qc>September 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2004</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>follicular</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Non-Hodgkins</keyword>
  <keyword>idiotype</keyword>
  <keyword>vaccine</keyword>
  <keyword>indolent follicular Non-Hodgkins Lymphoma</keyword>
  <keyword>tumor-derived</keyword>
  <keyword>B-cell</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

